Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia.

Gharabawi GM, Bossie CA, Lasser RA, Turkoz I, Rodriguez S, Chouinard G. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr Res. 2005;77(2-3):119-28. DOI: 10.1016/j.schres.2005.03.008. PubMed PMID: 15913963.

Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.

Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, et al. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study. Jama Psychiatry. 2015;72(9):927-34. DOI: 10.1001/jamapsychiatry.2015.0891. PubMed PMID: 26131622.

Drugs of abuse and increased risk of psychosis development.

Gururajan A, Manning EE, Klug M, van den Buuse M. Drugs of abuse and increased risk of psychosis development. Aust N Z J Psychiatry. 2012;46(12):1120-35. DOI: 10.1177/0004867412455232. PubMed PMID: 22833579.

Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis.

Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med. 2012;157(7):498-511. DOI: 10.7326/0003-4819-157-7-201210020-00525. PubMed PMID: 22893011.

The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review.

James A, James C, Thwaites T. The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review. Psychiatry Res. 2013;214(3):181-9. DOI: 10.1016/j.pscychresns.2013.07.012. PubMed PMID: 24139960.

Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.

Lerner V, Miodownik C. Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment. Curr Psychiatry Rep. 2011;13(4):295-304. DOI: 10.1007/s11920-011-0202-6. PubMed PMID: 21519907.

Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia.

Lin J, Wong B, Offord S, Mirski D. Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia. J Behav Health Serv Res. 2013;40(3):355-66. DOI: 10.1007/s11414-013-9329-z. PubMed PMID: 23579871.

Medical management of patients on clozapine: A guide for internists.

Lundblad W, Azzam PN, Gopalan P, Ross CA. Medical management of patients on clozapine: A guide for internists. J Hosp Med. 2015;10(8):537-43. DOI: 10.1002/jhm.2345. PubMed PMID: 25809850.

Long-acting injectable antipsychotics: recommendations for clinicians.

Malla A, Tibbo P, Chue P, Levy E, Manchanda R, Teehan M, et al. Long-acting injectable antipsychotics: recommendations for clinicians. Can J Psychiatry. 2013;58(5 Suppl 1):30S-5S. PubMed PMID: 23945065.

Long-acting injectable antipsychotics: evidence of effectiveness and use.

Manchanda R, Chue P, Malla A, Tibbo P, Roy M-A, Williams R, et al. Long-acting injectable antipsychotics: evidence of effectiveness and use. Can J Psychiatry. 2013;58(5 Suppl 1):5S-13S. PubMed PMID: 23945067.